C.M. Bidwell & Associates’s Quest Diagnostics DGX Stock Holding History

C.M. Bidwell & Associates’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,444	Closed	-$204K	–	537
2023 Q1	$204K	Buy	+1,444	New	+$207K	0.15%	120
2022 Q2	–	Sell	-385	Closed	-$53K	–	511
2022 Q1	$53K	Sell	385 -15	-4%	-$2.09K	0.03%	283
2021 Q4	$69K	Buy	+400	New	+$60.9K	0.04%	275
2021 Q2	–	Sell	-1,793	Closed	-$230K	–	582
2021 Q1	$230K	Buy	1,793 +899	+101%	+$111K	0.17%	111
2020 Q4	$107K	Buy	+894	New	+$109K	0.09%	224
2020 Q3	–	Sell	-2,375	Closed	-$271K	–	470
2020 Q2	$271K	Buy	+2,375	New	+$252K	0.25%	98
2016 Q3	–	Sell	-52,720	Closed	-$4.29M	–	275
2016 Q2	$4.29M	Buy	52,720 +3,510	+7%	+$267K	1.06%	24
2016 Q1	$3.52M	Buy	+49,210	New	+$3.3M	0.88%	68

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

C.M. Bidwell & Associates's DGX Position: Q2 2023 in Review

C.M. Bidwell & Associates sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 1,444 shares — an estimated $204K sold.

C.M. Bidwell & Associates first reported a position in DGX in Q1 2016 and held it in 8 quarters. The position peaked at $4.29M in Q2 2016. 818 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

C.M. Bidwell & Associates reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 1,444 Quest Diagnostics shares in Q2 2023, an estimated $204K.
C.M. Bidwell & Associates first reported a position in Quest Diagnostics in Q1 2016 and held it in 8 quarters.
C.M. Bidwell & Associates's Quest Diagnostics position peaked at $4.29M in Q2 2016.
818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2023, filed 14 Aug 2023.